LXGTF — Lexington Biosciences Holdings Income Statement
0.000.00%
Last trade - 00:00- $0.00m
- $0.00m
Annual income statement for Lexington Biosciences Holdings, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1.15 | 0.481 | 0.324 | 0.176 | 0.177 |
| Operating Profit | -1.15 | -0.481 | -0.324 | -0.176 | -0.177 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -1.27 | -0.481 | -0.324 | -0.176 | -0.177 |
| Net Income After Taxes | -1.27 | -0.481 | -0.324 | -0.176 | -0.177 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.27 | -0.481 | -0.324 | -0.176 | -0.177 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.27 | -0.481 | -0.324 | -0.176 | -0.177 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.173 | -0.04 | -0.012 | -0.006 | -0.006 |